{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Diagnosis and Main Criteria for Inclusion/Exclusion (Continued):', 'Main Exclusion (Continued):', '4.', 'Documented history of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac', 'symptoms consistent with New York Heart Association (NYHA) Class III - IV heart failure (refer to', 'Appendix F) within 6 months prior to randomization.', '5.', 'Documented history of capillary leak syndrome.', '6.', 'Grade 2 or higher pleural or pericardial effusion within 4 weeks of randomization or earlier history of', 'recurrent Grade 2 or higher effusions with ongoing requirement for pericardiocentesis or', 'thoracentesis.', '7.', 'Serious infection within 2 weeks prior to randomization, including any Grade 3 or higher (per NCI', 'CTCAE version 4.0) viral, bacterial, or fungal infection.', '8.', 'Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study', 'or for approximately 6 months after the last dose of blinded investigational product.', '9.', 'Male subject who is considering fathering a child or donating sperm during the study or for', 'approximately 6 months after the last dose of blinded investigational product.', '10. Systemic therapy with corticosteroids at > 10 mg/day prednisone or equivalent within 1 week prior to', 'randomization.', '11. Subject has a history of active malignancies other than SCLC within the past 2 years prior to study', 'entry, with the exception of in situ cancer which was curatively treated.', '12. Any prior exposure to a pyrrolobenzodiazepine (PBD-based)-or indolinobenzodiazepine-based drug,', 'prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity or other', 'contraindications to rovalpituzumab tesirine or excipient contained in the drug formulation.', '13. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells.', 'Investigational Products:', 'Rovalpituzumab tesirine or Placebo', 'Dexamethasone or Placebo', 'Doses:', 'Rovalpituzumab tesirine/Placebo: 0.3 mg/kg, Day 1 of each 6-week', 'cycle, omitting every third cycle.', 'Dexamethasone/Placebo 8 mg orally (PO) twice daily on Day -1, Day 1', '(the day of dosing), and Day 2 of each 6 week cycle, omitting every', 'third cycle.', 'Mode of Administration:', 'Rovalpituzumab tesirine/Placebo: Intravenous', 'Dexamethasone/Placebo: Oral', 'Duration of Treatment: Subjects will receive rovalpituzumab tesirine/placebo in combination with', 'dexamethasone/placebo on Day 1 of a 6-week cycle, omitting every third cycle until disease progression.', 'Criteria for Evaluation:', 'Efficacy: Efficacy assessments will consist of evaluations for tumor progression using Response', 'Evaluation Criteria in Solid Tumors (RECIST) v1.1 and will be based on a Central Radiographic', 'Assessment Committee (CRAC) review of medical images, as outlined in the Schedule of Assessments.', 'Additionally, efficacy will be assessed by overall survival.', 'Pharmacokinetic: Serum concentrations of rovalpituzumab tesirine ADC and the presence of anti-', 'therapeutic antibodies (ATA) will be determined.', '13']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Criteria for Evaluation (Continued):', 'Biomarkers: Pharmacodynamic and predictive biomarker assessments will include analyses of tumor', 'material and circulating tumor cells for DLL3 expression, blood samples for inflammatory, tumor, and', 'soluble markers. Samples may also be used for other nucleic acid or protein based exploratory', 'biomarkers to understand the sensitivity or resistance to rovalpituzumab tesirine and biology of SCLC.', 'Safety: Safety assessments include physical exam, vital signs, body weight, ECOG score, clinical', 'adverse events, laboratory tests (hematology, serum chemistries, urinalysis, and coagulation), ECGs,', 'echocardiogram, fluid retention questionnaire, radiographic images review for fluid retention, and', 'monitoring of concomitant medications.', 'Patient Reported Outcome (PRO):', 'Changes in the patient reported outcomes (PROs) EORTC QLQ-C30, EORTC QLQ-LC13, and', 'EQ-5D-5L from baseline will be assessed.', 'Statistical Methods:', 'Efficacy:', 'Progression-free survival (PFS) per CRAC and overall survival (OS) in patients with DLL3 high ED SCLC', 'are the two primary efficacy endpoints. To meet global regulatory requirements, a multiple testing', 'strategy will be implemented to control the family-wise type I error (alpha) for comparisons of', 'rovalpituzumab tesirine arm versus placebo arm with respect to progression-free survival (PFS) per', 'CRAC in DLL3 high patients, overall survival (OS) in DLL3high patients, PFS per CRAC in randomized', 'patients, OS in randomized patients, and physical functioning scale score (EORTC QLQ-C30) in the', 'randomized set.', 'The following null hypotheses are considered:', 'Two hypotheses in H01 are H01a and Holb.', 'H01a: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in DLL3hig set.', 'Hoib: Rovalpituzumab tesirine arm is not superior to placebo arm in os in DLL3 high set.', 'H02: Rovalpituzumab tesirine arm is not superior to placebo arm in os in randomized set.', 'H03: Rovalpituzumab tesirine arm is not superior to placebo arm in PFS per CRAC in randomized set.', 'H04: Rovalpituzumab tesirine arm is not superior to placebo arm in physical functioning scale score', '(EORTC QLQ-C30) in randomized set.', 'The null hypotheses will be tested in a fixed sequence of {H01a, Holb, H02, H03, and H04} in order. To', 'maintain the family-wise type I error for the study, the null hypotheses in H01 (H01a and H01b) will be first', 'tested with an alpha-split approach. The one-sided alpha of 0.25% and 2.25% will be assigned for PFS', 'and OS hypothesis in H01, respectively. Out of one-sided alpha of 2.25% allocated to OS hypothesis', '(Ho1b), the one-sided alpha of 10-6 will be spent for the early look at the OS data for futility analysis. If', 'the hypothesis for PFS in H01 (H01a) is rejected the one-sided alpha of 0.25% will be recycled to the OS', 'hypothesis in H01 (H01b). Hence, the hypothesis for OS in H01 (H01b) will be tested either at a one-sided', '2.4999% or one-sided 2.2499% level of significance depending on the PFS hypothesis in H01 a is rejected', 'or not.', 'If either PFS or os endpoint reaches statistical significance, the study is considered positive. No further', 'tests will be performed if the os endpoint in DLL3high population (H01b) does not reach statistical', 'significance.', '14']\n\n###\n\n", "completion": "END"}